Recipients of intravenous (IV) iron (n = 688,183) enrolled in the fee-for-service Medicare program from January 2003 to December 2013 were the focus of recent study, which compared the risk of anaphylaxis among patients and products.
Recipients of intravenous (IV) iron (n = 688,183) enrolled in the fee-for-service Medicare program from January 2003 to December 2013 were the focus of recent study, which compared the risk of anaphylaxis among patients and products.